Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.

Graney, Bridget A; Lee, Joyce S

Graney, Bridget A; Lee, Joyce S.

Afiliação

Graney BA; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, bridget.graney@ucdenver.edu.
Lee JS; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, bridget.graney@ucdenver.edu.

Patient Relat Outcome Meas ; 9: 321-328, 2018.

Article em En | MEDLINE | ID: mdl-30288134

Palavras-chave

idiopathic pulmonary fibrosis; interstitial lung disease; nintedanib; patient-reported outcome measures; pirfenidone; quality of life

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article